The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
Key facts
- Where
- Jhajjar, IndiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07565987, who can take part
Where in India
- Nci, Aiims-JhajjarJhajjar, IndiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- All India Institute of Medical Sciences
- Trial code
- NCT07565987
- Record updated
- 24 September 2026
- Original description
The aim of the study is to test the feasibility \& loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor/lymph nodes if tumors/lymph node size with ≤ 6cms in size.Read full original descriptionShow less
The APRIL Trial: A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
The aim of the study is to test the feasibility \& loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor/lymph nodes if tumors/lymph node size with ≤ 6cms in size.
Inclusion: Aged 18 or above and less than 75 years; Histologically proven non-small cell lung cancer; Stage T1-4, N1-3, M0 with maximum tumor size less than 6 cms and ≤ 3 stations of largest lymph node size less than 4 cms; ECOG status 0-1; Available to attend long term follow- up; Written informed consent for treatment.
Exclusion: Previous radiotherapy to thorax; Patients on anticoagulant therapy \& ultra-central cavitary tumors; Metastatic disease; Age< 18 or > 75 years; Tumor size > 6cm; Involved Lymph node size greater than 4 cms \& more than 3 station of lymph nodes involved; Patients with superior vena cava obstruction; Tumor invading/encasing the proximal bronchial tree/, esophagus, pericardium; Small cell histology; Poor performance status ECOG 2-3; Immunocompromised states; Viral Markers negative; Pregnant women.